🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge
Demo corpus. Scores are computed on a select set of biomedical paper/datasets and may be inaccurate for papers outside this corpus — DataRank relies on network effects that improve with scale. We aim to expand this into a fully open resource pending additional funding.

Effects of Intensive Glucose Lowering in Type 2 Diabetes

New England Journal of Medicine(2008)10.1056/nejmoa0802743Source: DataRank Database

Effects of Intensive Glucose Lowering in Type 2 Diabetes is a research paper published in New England Journal of Medicine (2008). On theSindex it has a DataRank of 1.3. It has been cited 7,857 times.

N/A
1.3DataRank · unranked
1.3
Open Access7857 citations · base score 9.0
Cite:
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Abstract

As compared with standard therapy, the use of intensive therapy to target normal glycated hemoglobin levels for 3.5 years increased mortality and did not significantly reduce major cardiovascular events. These findings identify a previously unrecognized harm of intensive glucose lowering in high-risk patients with type 2 diabetes. (ClinicalTrials.gov number, NCT00000620.)

Data sources & pipeline
Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring
Enrichment:Pending

FAIR Checklist

Context only (not used in score)
Findable (1/2)
  • Has DOI
Accessible (1/2)
  • Open Access
Interoperable (0/2)
    Reusable (0/3)

      FAIR checklist signals are shown for context only and do not affect DataRank scoring.

      DataRank Breakdown

      Base Score 100%Citation Network 0%

      Base Score Contribution

      1.3

      From this paper's citation signal

      Citation Network Contribution

      0

      Citation network not refreshed for this result

      This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

      Learn more about DataRank methodology →
      Why this DataRank?

      DataRank blends this paper's own citation count with the influence of the papers that cite it. Here, roughly 100% comes from its base citations and 0% from the citation network.

      Base score B(p)
      log1p(citation_count) — grows sub-linearly, so a paper with 1,000 citations is not 10× a paper with 100.
      Network N(p)
      Σ over citers of log1p(Cq) ÷ max(outdegreeq, 1). Being cited by a highly-cited paper with few references counts most.
      Damping factor d = 0.85
      DataRank = (1−d)·B(p) + d·N(p) — the two cards above are each already multiplied by their share.
      Self-citations excluded
      Citers sharing any OpenAlex author ID with this paper are filtered out before the network sum.

      Citers are pulled from OpenAlex sorted by cited_by_count:descand capped per paper, so when the cap binds we keep the highest-signal references and the score is reproducible across reruns.

      Read the full methodology →

      Authors (13)

      Michael E. Miller,Robert P. Byington,David C. GoffORCID,J. Thomas Bigger,John B. BuseORCID

      Related Papers (10)

      New England Journal of Medicine(2008)
      co-citedsame journal
      10.1056/nejmoa0802987
      New England Journal of Medicine(2009)
      co-citedsame journal
      10.1056/nejmoa0904327
      New England Journal of Medicine(2007)
      co-citedsame journal
      10.1056/nejmoa0706482
      Adherence to Medication
      N/A
      1.3DataRank · unranked
      New England Journal of Medicine(2005)
      co-citedsame journal
      10.1056/nejmra050100